Cargando…
Advances in Diagnostics and Drug Discovery against Resistant and Latent Tuberculosis Infection
Latent tuberculosis infection (LTBI) represents a subclinical, asymptomatic mycobacterial state affecting approximately 25% of the global population. The substantial prevalence of LTBI, combined with the risk of progressing to active tuberculosis, underscores its central role in the increasing incid...
Autores principales: | Shleider Carnero Canales, Christian, Marquez Cazorla, Jessica, Furtado Torres, André Henrique, Monteiro Filardi, Eloise T., Di Filippo, Leonardo Delello, Costa, Paulo Inácio, Roque-Borda, Cesar Augusto, Pavan, Fernando Rogério |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610444/ https://www.ncbi.nlm.nih.gov/pubmed/37896169 http://dx.doi.org/10.3390/pharmaceutics15102409 |
Ejemplares similares
-
Delivery Strategies of Probiotics from Nano- and Microparticles: Trends in the Treatment of Inflammatory Bowel Disease—An Overview
por: Lopes, Sílvio André, et al.
Publicado: (2023) -
In Vitro Skin Co-Delivery and Antibacterial Properties of Chitosan-Based Microparticles Containing Ascorbic Acid and Nicotinamide
por: Di Filippo, Leonardo Delello, et al.
Publicado: (2022) -
Pharmaceutical Biotechnology
por: Roque-Borda, Cesar Augusto, et al.
Publicado: (2022) -
Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria
por: Roque-Borda, Cesar Augusto, et al.
Publicado: (2021) -
Nanobiotechnology with Therapeutically Relevant Macromolecules from Animal Venoms: Venoms, Toxins, and Antimicrobial Peptides
por: Roque-Borda, Cesar Augusto, et al.
Publicado: (2022)